Author + information
- 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 2Tiantan Clinical Trial and Research Center for Stroke, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
To explore the changes in health-related quality of life (HRQoL) during blood pressure control and blood lipid lowering therapies, and to investigate the variations in HRQoL between different interventions or between different blood pressure/lipid levels.
We conducted a 2′2 factorial-designed randomized controlled trial in 180 clinical centers in China. At baseline, participants were randomly assigned to amlodipine + compound amiloride group or amlodipine + telmisartan group for blood pressure control treatment, and to statin group or routine intervention group for blood lipid lowering treatment. Follow-up lasted for four years. HRQoL was assessed using the EuroQol five dimensions three levels (EQ-5D-3L) questionnaire every year.
Among 13,542 participants enrolled in the study, 13,499 (99.7%) were eligible for analysis. Baseline characteristics were balanced among the intervention groups. All dimensions of the EQ-5D-3L descriptive system had little problems at baseline, and were well preserved during follow-up. EuroQol visual analogue scale (EQ VAS) as well as EQ-5D-3L Index were improved over time (Ptrend<0.0001); the improvements were not differed between intervention groups (P=0.9980 for EQ VAS; P=0.9080 for EQ-5D-3L Index), but between patients who whether or not reached the treatment targets (P=0.0018 for EQ-5D-3L Index).
HRQoL is associated with blood pressure levels, but not with specific antihypertensive or lipid-lowering drugs. Blood pressure control and blood lipid lowering therapies are recommended in Chinese patients to control the disease and to enhance the quality of life.